HR2450Referred to Committee

Prescription Drug Transparency and Affordability Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-03-27
Introduced
3
Cosponsors
HR
ⓘ
Type

Sponsor

Kristen McDonald Rivet
Kristen McDonald Rivet
Democrat · MI · Representative
Votes with party: 91.9% (592 recorded votes)

Full profile: /officials/M001237

Source: Congress.gov · FEC

Cosponsors (3)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

2025-03-27

Source: Congress.gov

Committee Activity

Currently in

Previously

Plain-English Summary

This bill would require pharmaceutical companies to disclose more information about how they set drug prices and would give the government more power to negotiate lower prices for medications, particularly for Medicare patients. The changes would likely affect both drug manufacturers and patients who struggle to afford prescription medications. The bill has been referred to multiple House committees for review and consideration.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.